Venue suggestions

Venue Recommendations

as_is

None. The editor's verdict is "minor," which means the paper is sound in substance but has calibration and reporting gaps that must be addressed before it is ready for publication at a peer-reviewed venue. Submitting as-is would invite desk rejection or major revision requests at any journal that applies the same standard.

---

after_revision

1. Biotechnology and Bioengineering

Fit: This is the natural home for this work. The journal publishes detailed bioprocess development, scale-up, and cGMP manufacturing papers. The reference standard here is Dey et al. (2018) on BG505 SOSIP.664 cGMP production — published in this exact journal — which the authors cite and build upon. The scope explicitly covers cell line development, upstream optimisation, downstream purification, product characterisation, and viral clearance. The audience includes bioprocess engineers, manufacturing scientists, and vaccine developers who will use the parameter tables and robustness envelopes directly.

Why it fits after revision: Once the genetic stability data are reported (or the claim removed), the reference-standard confound is addressed, and the quantitative claims are grounded in actual numbers, this becomes a complete technical record at the standard the journal expects. The editor's required revisions are all about transparency and precision, not about missing experiments or flawed methodology.

Acceptance odds: High (70–80%). The work is sound, the contribution is clear (enabling a designed immunogen to reach the clinic with a documented, transferable process), and the detail level matches the journal's expectations. The revisions are substantial in number but straightforward in execution — they are about reporting what you have, not doing new work.

---

2. Vaccine

Fit: Vaccine publishes vaccine development, manufacturing, and clinical translation papers. This manuscript documents the translation of a rationally designed HIV-1 Env trimer from preclinical efficacy (Steichen et al., 2024) to clinical-grade material now in HVTN 144. The scope includes bioprocess development and GMP manufacturing as essential components of vaccine translation. The audience includes vaccine researchers, immunologists, and translational scientists who need to understand how designed immunogens move to the clinic.

Why it fits after revision: The revisions strengthen the clinical translation narrative by clarifying what was actually manufactured (one GMP batch, not "multiple batches") and ensuring that the process documentation is reproducible. Vaccine readers care less about the fine details of Ambr®250 optimisation than Biotechnology and Bioengineering readers do, but they care deeply about whether the process is sound and whether the final product meets specifications — both of which are well-established here.

Acceptance odds: Moderate-to-high (60–75%). The paper is a solid translational contribution, but Vaccine may view it as more of a methods/manufacturing paper than a vaccine-science paper. The clinical context (HVTN 144) is a strength. The revisions are compatible with the journal's scope and standards.

---

3. Journal of Pharmaceutical and Biomedical Analysis (or Pharmaceutical Research)

Fit: These journals publish analytical method development, product characterisation, and bioprocess validation papers. The manuscript's strength in orthogonal analytical methods (SE-HPLC, RP-HPLC, BLI, two glycoproteomics methods, nsEM, viral clearance) and the detailed characterisation of intermediates and final product fit well. The scope includes cGMP manufacturing support and validation.

Why it fits after revision: The analytical and characterisation sections are thorough and would be of high value to analytical and manufacturing scientists. The revisions ensure that every quantitative claim (purity, impurity clearance, potency) is grounded in actual numbers and acceptance criteria. This is a natural fit for a journal focused on analytical rigor.

Acceptance odds: Moderate (55–70%). These journals are narrower in scope than Biotechnology and Bioengineering, so the upstream process development and clone ranking may be less central to the audience. However, the analytical and characterisation work is substantial enough to carry the paper on its own merits.

---

alternative

1. bioRxiv (preprint server)

Fit: If the authors wish to establish priority and get the work into the scientific record quickly while completing revisions, bioRxiv is appropriate. The manuscript is a complete technical record suitable for preprint. The required revisions can be addressed in a revised version posted to the same preprint, which can then be cited in the journal submission.

Why this is useful: Allows the authors to publish the detailed process documentation immediately (important for practitioners scaling other Env trimers) while working through journal peer review. The HVTN 144 trial is active, so early availability of the manufacturing details has scientific value.

---

2. Processes (MDPI open-access journal)

Fit: This is a broad, open-access journal focused on bioprocess development, manufacturing, and scale-up. It explicitly welcomes detailed process documentation, parameter tables, and robustness studies. The scope includes cell line development, upstream and downstream optimisation, and product characterisation.

Why it fits: Lower barrier to acceptance than Biotechnology and Bioengineering, and the journal values the kind of comprehensive technical detail this manuscript provides. Open access ensures wide reach among bioprocess practitioners.

Acceptance odds: High (75–85%), but with a caveat: the journal is lower-tier in prestige and impact. This is a good fallback if the authors face unexpected resistance at the primary venues, or if they want to ensure rapid publication while pursuing a higher-impact outlet in parallel.

---

3. mBio (if the immunology angle is emphasised)

Fit: If the authors reframe the paper to emphasise the immunological validation (the preclinical priming of BG18-class B cells in macaques, now being tested in HVTN 144) alongside the manufacturing, mBio might be interested. The journal publishes vaccine development and translational immunology.

Why this is a fallback: The current manuscript is primarily a manufacturing paper; the immunology is context, not data. Reframing would require adding discussion of the immunological objectives and how the manufacturing specifications support them. This is not a natural fit, but it is possible if the authors want to reach an immunology audience.

Acceptance odds: Low-to-moderate (40–55%). The paper would need substantial rewriting to centre the immunology, and mBio may still view it as primarily a methods paper. Not recommended unless the primary venues decline.

---

Summary and Recommendation

Primary target after revision: Biotechnology and Bioengineering. This is where the work belongs. The journal has published the direct precedent (Dey et al., 2018), the audience is exactly the practitioners who will use this process, and the scope is a perfect match. The required revisions are all achievable without new experiments.

Secondary target: Vaccine, if the authors want to emphasise the clinical translation and immunological context over the bioprocess details.

Fallback: Processes (MDPI) if the primary venues decline, or bioRxiv if the authors want immediate publication while pursuing journal review.

Do not submit as-is to any peer-reviewed journal. The editor's required revisions are not optional; they address material gaps in reporting that would trigger major revision or desk rejection at any competent review. The good news is that they are all fixable from existing data and records.